Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2022-07-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于更换持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of continuous supervision sponsor representatives for a company listed on the stock exchange. It details the replacement of individuals responsible for ongoing sponsorship duties related to the company's IPO and convertible bond issuance. There is no financial data, report, or detailed analysis presented. The document is short (1026 characters) and serves as a formal notification of management/sponsor representative changes rather than a financial report or detailed management discussion. This fits the category of Board/Management Information (MANG), which includes announcements of changes in senior management or board-related roles.
2022-07-28 Chinese
2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2022 second extraordinary general meeting of shareholders of Shenzhen Microchip Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholders' meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 1777 characters, which is relatively short but contains substantive voting results and meeting details, not just a brief notice or report publication announcement. Therefore, it is classified as DVA with high confidence.
2022-07-27 Chinese
上海市通力律师事务所关于深圳微芯生物科技股份有限公司2022年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and validity of a company's 2022 second extraordinary general meeting (临时股东大会). It discusses the legality of the meeting's notice, attendance, voting procedures, and results. There is no financial data, earnings information, or report publication. The document is not an announcement of voting results but a legal opinion supporting the meeting's compliance. This fits best under Regulatory Filings (RNS) as it is a compliance/legal document related to a shareholder meeting but not the meeting materials or voting results themselves.
2022-07-27 Chinese
深圳微芯生物科技股份有限公司向不特定对象发行可转换公司债券上市公告书
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance and listing of convertible corporate bonds by Shenzhen Chipscreen Biosciences Co., Ltd. It includes extensive information about the bond issuance, company background, shareholding structure, product pipeline, and regulatory approvals. The document is titled as a "上市公告书" which translates to "Listing Announcement" or "Offering Circular" for convertible bonds. It is not a financial report like an annual or interim report, nor is it a transcript, audit report, or management report. It is a formal announcement related to capital raising via convertible bonds and their listing on the Shanghai Stock Exchange. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual announcement, not just a brief notice or report publication announcement.
2022-07-25 Chinese
2022年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2022 Second Extraordinary General Meeting of Shareholders" of Shenzhen Microchip Biotechnology Co., Ltd. It includes detailed meeting instructions, agenda, voting procedures, and a specific proposal regarding an investment and related party transaction. The content is focused on the shareholder meeting process and materials rather than the results of voting or a summary of the meeting outcomes. The document length is 4164 characters, which is relatively short and consistent with meeting materials rather than a full report. It is not a voting results announcement (DVA) because it does not provide final voting results or resolutions passed. It is not an announcement of a report publication (RPA) because it contains substantive meeting content. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2022-07-19 Chinese
安信证券股份有限公司关于深圳微芯生物科技股份有限公司子公司引入外部投资者暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a sponsoring securities company (安信证券股份有限公司) regarding an external investment and related party transaction involving a subsidiary (成都微芯新域生物技术有限公司) of 深圳微芯生物科技股份有限公司. It includes comprehensive information about the transaction, parties involved, investment amounts, governance arrangements, pricing basis, and the sponsor's verification opinion. The document is lengthy (over 8,000 characters) and contains substantive details about the transaction and related party review, not just an announcement or summary. It is not a financial report like an annual or interim report, nor is it a simple announcement or voting result. It is a formal audit or verification opinion on a related party transaction and investment, which fits the category of an Audit Report / Information (AR). Q1 2022
2022-07-11 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.